6-氨基-2-[[2-(羧基甲基)-3-氧代-2-氮杂双环[5.4.0]十一碳-7,9,11-三烯-4-基]氨基]己酸 | 97878-35-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 6-氨基-2-[[2-(羧基甲基)-3-氧代-2-氮杂双环[5.4.0]十一碳-7,9,11-三烯-4-基]氨基]己酸
• 中文别名: 里苯泽卜瑞；氯十三二基锡烷
• 英文名称: Libenzapril
• 英文别名: 3(S)-<<(1S)-5-amino-1-carboxypentyl>amino>-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid；3(S)-[[(1S)-5-amino-1-carboxypentyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid；3-(5-amino-1-carboxy-1S-pentyl)amino-2,3,4,5-tetrahydro-2-oxo-3S-1H-1-benzazepine-1-acetic acid；3(S)-[((1S)-5-amino-1-carboxypentyl)amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid；(2S)-6-amino-2-[[(3S)-1-(carboxymethyl)-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]hexanoic acid
• CAS: 97878-35-8
• 化学式: C₁₈H₂₅N₃O₅
• 分子量: 363.414
• InChiKey: AXTCRUUITQKBAV-KBPBESRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-氨基-2-[[2-(羧基甲基)-3-氧代-2-氮杂双环[5.4.0]十一碳-7,9,11-三烯-4-基]氨基]己酸 、 1-<5-<5-chloro-1-methyl-2-(3-pyridinyl)-1H-indol-3-yl>pentanoyl>piperidin-4-one 以 甲醇 、 溶剂黄146 为溶剂， 反应 1.0h， 生成 (S)-2-((S)-1-Carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-6-{1-[6-(5-chloro-1-methyl-2-pyridin-3-yl-1H-indol-3-yl)-hexanoyl]-piperidin-4-ylideneamino}-hexanoic acid
  参考文献：
  名称：

  Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors

  摘要：

  A variety of compounds were prepared to determine whether dual angiotensin converting enzyme (ACE)/thromboxane synthase (TxS) inhibition could be obtained in the same molecule. These compounds would be used to explore the concept that a dual inhibitor would have superior antihypertensive activity in the spontaneous hypertensive rat compared to an ACE inhibitor. Potent in vitro dual ACE and TxS inhibition was obtained in the same molecule with five series of compounds. Potent blood pressure lowering in the SHR was observed after oral administration of 8b and 11. However, a correlation between blood pressure lowering and the Al presser response inhibition was not observed. The blood pressure-lowering actions of enalapril were significantly potentiated by concurrent administration of 3, a thromboxane synthase inhibitor. Analysis of the area under the curve for 24 h showed nearly a doubling of the blood pressure-lowering effect.

  DOI：

  10.1021/jm00038a011
• 作为产物：
  描述：

  ethyl 3-amino-2,3,4,5-tetrahydro-1H-<1>benzazepin-2-one-1-acetate 在 palladium on activated charcoal sodium hydroxide 、 亚硝酸特丁酯 、 二丁基二氯化锡 、 氢气 、 sodium cyanoborohydride 、 溶剂黄146 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 乙醇 、 氯仿 、 水 为溶剂， 25.0 ℃ 、303.98 kPa 条件下， 反应 67.25h， 生成 6-氨基-2-[[2-(羧基甲基)-3-氧代-2-氮杂双环[5.4.0]十一碳-7,9,11-三烯-4-基]氨基]己酸
  参考文献：
  名称：

  Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives

  摘要：

  The preparation of a series of 3-amino-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-1-acetic acid derivatives 5a-y by reductive amination of 2,3,4,5-tetrahydro-1H-1-benzazepine-2,3-dione (7) with L-amino acid derivatives is described. The compounds were tested for inhibition of angiotensin converting enzyme. The structure-activity profile of the series is discussed. Compound 5a was especially potent when tested in dogs for inhibition of angiotensin I pressor response, having an ID50 = 0.07 mg/kg po.

  DOI：

  10.1021/jm00149a010

文献信息

• Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
  申请人：Graziano P. Michael

  公开号：US20050096307A1

  公开（公告）日：2005-05-05

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one lipid modulating agent; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种脂质调节剂；和(b)至少一种取代的噁唑烷酮或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖以及降低血浆中甾醇或5α-甾烷醇的水平。
• Combinations of substituted azetidinones and CB1 antagonists
  申请人：Veltri P. Enrico

  公开号：US20060069080A1

  公开（公告）日：2006-03-30

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB 1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种选择性CB1拮抗剂；和(b)至少一种取代的氮杂环丁烷或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖、代谢综合征以及降低血浆中的甾醇或5α-甾烷醇水平。
• [EN] DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE PRESENTANT UNE ACTIVITE D'INHIBITION D'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061451A1

  公开（公告）日：2005-07-07

  Compounds of formula (XV): [Chemical formula should be inserted here. Please see paper copy] (XV) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  公式（XV）的化合物：[应在此处插入化学公式。请参见纸质副本]（XV）（其中变量组如内部定义）药物可接受的盐、溶剂化物、这些盐的溶剂化物和前药及其用作治疗高脂血症的胆固醇吸收抑制剂。还描述了它们的制造过程和含有它们的药物组合物。
• Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof
  申请人：——

  公开号：US20040058977A1

  公开（公告）日：2004-03-25

  The present invention relates to sulfonyl-containing 2,3-diarylindole, especially to new compounds of general Formula, to a preparation method for their preparation, to pharmaceutical compositions containing said compound, and to the medical use thereof in the treatment of diseases relating to the inhibition of cyclooxygenase-2 (COX-2).

  本发明涉及含砜基的2,3-二芳基吲哚，特别涉及一般式的新化合物，其制备方法，含有该化合物的药物组合物，以及在治疗与环氧合酶-2（COX-2）抑制有关的疾病中的医疗用途。
• [EN] SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS<br/>[FR] PIPÉRAZINES SUBSTITUÉES EN TANT QU'ANTAGONISTES DE CB1
  申请人：SCHERING CORP

  公开号：WO2009005645A1

  公开（公告）日：2009-01-08

  Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  化合物式(I)或其药用可接受的盐、溶剂合物或酯，可用于治疗由CB1受体介导的疾病或症状，如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（例如戒烟）、胃肠道疾病和心血管疾病。